Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers explore gene treatment to obliterate HIV before it does damage

26.05.2004


Volunteers now sought for Stanford trial



Doctors may someday have a new way to combat AIDS by going straight to the source: destroying the virus before it has a chance to wreak havoc on a patient’s immune system.

Thomas Merigan, MD, the George and Lucy Becker Professor of Medicine in infectious diseases at Stanford University School of Medicine, is seeking volunteers for a study to test a possible method of empowering an infected person’s own cells to destroy HIV as it enters the cell. The process involves removing the patient’s stem cells - the ones in the bloodstream that form the different immune system cell types that HIV infects, such as T cells and macrophages - and inserting a gene that produces an HIV-obliterating enzyme.


"This is a broad-spectrum treatment that could integrate well with other therapies as the disease progresses, as it will in all patients eventually," said Merigan, who is collaborating with other researchers at UCLA and St. Vincent’s Hospital in Sydney, Australia, under the sponsorship of Johnson & Johnson Research. "The goal is to genetically engineer the cells and make them resistant to infection."

The strategy developed by Merigan and his colleagues relies on the fact that the genetic information of HIV is encoded in RNA rather than DNA. Enzymes called ribozymes can chew up RNA at very specific sites, rendering it inactive. If a ribozyme specific to HIV RNA were present inside the cells that the virus infects, then it could constitute a first-line defense against the invasion. Even if HIV did make it into the cell and replicated, the ribozyme could potentially cleave the HIV RNA at various steps during the virus’ life cycle. With this unique approach to warding off HIV infection, the enzyme produced by a person’s own vulnerable cells could demolish the critical genetic instructions of HIV while not affecting his or her RNA.

"With this technique, we’d like to be able to offer an additional approach for patients who in their own minds appear to be doing quite well," said Merigan. "We know there is a sufficient risk that patients will eventually need more than the 19 drugs currently available."

A total of 70 patients will be enrolled at three sites for this stage of the testing. The participants will be randomly assigned to receive either the ribozyme gene therapy or a dummy gene. Johnson & Johnson Research produces the reagents used for introducing ribozyme into the blood stem cells.

In the field of AIDS treatment, there is recognition that an approach like the one Merigan is testing would be a huge development in the ability to combat HIV. David Evans, an information and advocacy associate for Project Inform, a San Francisco-based national nonprofit working to end the AIDS epidemic, said, "Experiments of this type fall perfectly in line with Project Inform’s agenda to refocus researchers toward a cure for HIV rather than indefinite treatment with costly antiviral drugs that consistently lead to drug resistance and long-term toxicities."

Martin Delaney, founding director of Project Inform, said he applauds the researchers for their persistence and continued interest in developing new treatments for HIV/AIDS, but added, "It is too early to comment on the potential of this particular experiment and, even if successful, it will be several years before the results can be turned into a widely accessible therapy."

Merigan said that similar studies testing the strategy of using gene therapy in more than 1,200 patients have proven the technique to be safe. The safety studies for the current trial looked at a total of 14 patients and found no safety concerns.

Merigan discussed a scare a few years ago when two babies undergoing gene therapy developed leukemia, which was successfully treated. He noted that the HIV trial had been delayed for two years while the trial’s safety design was examined by the National Institutes of Health, the U.S. Food and Drug Administration and local review boards. He said the verdict was that the immune system of adults with HIV differs greatly from that of babies, whose immune systems are not fully formed, and that they should not face the same risk.

The criteria for potential study participants are strict at this stage: men and women with HIV who are between ages 18 and 45, on only the first or second round of anti-retroviral therapy, a relatively low amount of virus in the blood (less than 50 particles per milliliter of blood) and a reasonably high level of T cells (300 cells per microliter of blood or greater). Pregnant women or those with any AIDS-related illnesses will not be included in this trial. Those who are interested should call (650) 723-6231.


Others in the study team in the division of infectious diseases at Stanford include Andrew Zolopa, MD, associate professor of medicine; Michael Harbour, MD, clinical instructor; Debbie Slamowitz, study coordinator for clinical trials; Jane Norris and Sandy Valle, physician assistants; Patricia Cain and Sylvia Stoudt, staff nurses; and Mark Winters, research assistant.

Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital at Stanford. For more information, please visit the Web site of the medical center’s Office of Communication & Public Affairs at http://mednews.stanford.edu.

PRINT MEDIA CONTACT: Amy Adams at (650) 723-3900 (amyadams@stanford.edu)
BROADCAST MEDIA CONTACT: M.A. Malone at (650) 723-6912 (mamalone@stanford.edu)

Amy Adams | EurekAlert!
Further information:
http://mednews.stanford.edu

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>